Analysts BTIG initiate coverage of Absci Corporation (ABSI) with a buy rating and $9 price target, citing potential for ABS-201 in hair loss treatment
Absci Corporation's innovative hair loss treatment, ABS-201, has garnered a buy rating from BTIG, with a projected peak sales potential of $2.2 billion, indicating significant market opportunity in a largely underserved sector.